Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Price, Quote, News and Overview

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

45.46  -0.14 (-0.31%)

After market: 44.5827 -0.88 (-1.93%)

EXAS Quote, Performance and Key Statistics

EXACT SCIENCES CORP

NASDAQ:EXAS (4/25/2025, 8:04:01 PM)

After market: 44.5827 -0.88 (-1.93%)

45.46

-0.14 (-0.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High72.83
52 Week Low39.97
Market Cap8.44B
Shares185.76M
Float183.06M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-01 2025-05-01/amc
IPO01-30 2001-01-30


EXAS short term performance overview.The bars show the price performance of EXAS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

EXAS long term performance overview.The bars show the price performance of EXAS in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of EXAS is 45.46 USD. In the past month the price increased by 1.04%. In the past year, price decreased by -22.75%.

EXACT SCIENCES CORP / EXAS Daily stock chart

EXAS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About EXAS

Company Profile

EXAS logo image EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Company Info

EXACT SCIENCES CORP

5505 Endeavor Lane

Madison WISCONSIN 53719 US

CEO: Kevin T. Conroy

Employees: 6550

Company Website: https://www.exactsciences.com/

Investor Relations: https://investor.exactsciences.com/investor-relations/default.aspx

Phone: 16082845700

EXACT SCIENCES CORP / EXAS FAQ

What is the stock price of EXACT SCIENCES CORP today?

The current stock price of EXAS is 45.46 USD. The price decreased by -0.31% in the last trading session.


What is the ticker symbol for EXACT SCIENCES CORP stock?

The exchange symbol of EXACT SCIENCES CORP is EXAS and it is listed on the Nasdaq exchange.


On which exchange is EXAS stock listed?

EXAS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EXACT SCIENCES CORP stock?

33 analysts have analysed EXAS and the average price target is 68.72 USD. This implies a price increase of 51.17% is expected in the next year compared to the current price of 45.46. Check the EXACT SCIENCES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EXACT SCIENCES CORP worth?

EXACT SCIENCES CORP (EXAS) has a market capitalization of 8.44B USD. This makes EXAS a Mid Cap stock.


How many employees does EXACT SCIENCES CORP have?

EXACT SCIENCES CORP (EXAS) currently has 6550 employees.


What are the support and resistance levels for EXACT SCIENCES CORP (EXAS) stock?

EXACT SCIENCES CORP (EXAS) has a support level at 42.49 and a resistance level at 45.47. Check the full technical report for a detailed analysis of EXAS support and resistance levels.


Is EXACT SCIENCES CORP (EXAS) expected to grow?

The Revenue of EXACT SCIENCES CORP (EXAS) is expected to grow by 11.21% in the next year. Check the estimates tab for more information on the EXAS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EXACT SCIENCES CORP (EXAS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EXACT SCIENCES CORP (EXAS) stock pay dividends?

EXAS does not pay a dividend.


When does EXACT SCIENCES CORP (EXAS) report earnings?

EXACT SCIENCES CORP (EXAS) will report earnings on 2025-05-01, after the market close.


What is the Price/Earnings (PE) ratio of EXACT SCIENCES CORP (EXAS)?

EXACT SCIENCES CORP (EXAS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.57).


What is the Short Interest ratio of EXACT SCIENCES CORP (EXAS) stock?

The outstanding short interest for EXACT SCIENCES CORP (EXAS) is 6.1% of its float. Check the ownership tab for more information on the EXAS short interest.


EXAS Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to EXAS. When comparing the yearly performance of all stocks, EXAS is a bad performer in the overall market: 77.25% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

EXAS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to EXAS. EXAS may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

EXAS Financial Highlights

Over the last trailing twelve months EXAS reported a non-GAAP Earnings per Share(EPS) of -5.57. The EPS decreased by -388.6% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -17.36%
ROE -42.83%
Debt/Equity 0.97
Chartmill High Growth Momentum
EPS Q2Q%-1629.63%
Sales Q2Q%10.29%
EPS 1Y (TTM)-388.6%
Revenue 1Y (TTM)10.36%

EXAS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to EXAS. The Buy consensus is the average rating of analysts ratings from 33 analysts.

For the next year, analysts expect an EPS growth of 91.39% and a revenue growth 11.21% for EXAS


Ownership
Inst Owners100.85%
Ins Owners0.99%
Short Float %6.1%
Short Ratio4.45
Analysts
Analysts84.85
Price Target68.72 (51.17%)
EPS Next Y91.39%
Revenue Next Year11.21%